Permanent prostate brachytherapy (PPB) in patients with localized prostate cancer is an effective treatment modality that appears to offers comparable biochemical freedom from disease as radical prostatectomy or external beam radiotherapy (XRT). 1 -7 Nonetheless, the use of combined external radiation and brachytherapy versus brachytherapy alone remains a controversial issue. While the recommendations proposed by the American Brachytherapy Society (ABS) have guided the practice of prostate brachytherapy over the last several years, there are others that have reported that combined external radiation and brachytherapy (combined modality therapy-CMT) should be performed for all patients regardless of risk. 8, 9 This current study provides additional follow-up on our previous review of monotherapy versus CMT in patients treated with PPB having localized prostate cancer and provides more mature results on whether there is a difference in PSA-relapse-free survival (PSA-RFS) based on treatment method. 10 Further, a matchedpair analysis was performed to correct for pretreatment variables.
Materials and methods
One thousand four hundred and seventy-six patients (pts) with T1/T2 prostate cancer staged by the AJCC 5th edition (T1NX, T2NX) treated with PPB with curative intent are included in this study cohort. 11 All patients had biopsy proven adenocarcinoma. All patients were clinically staged by the treating physician (L.P.). A transrectal ultrasound was performed to assess prostate volume and only a prostate volume of less than 60 g was deemed eligible for PPB. Two hundred and seventy-six patients received neoadjuvant androgen deprivation (NAAD) to cyto-reduce the prostate volume for 3 -7 months (mean 3.5 months) before undergoing PPB (n ¼ 120) or received NAAD as started by the patients' urologist (n ¼ 156).
The treatment criteria for monotherapy or CMT was loosely based on the ABS definitions, however patient self-selection and preference allowed for an overlap of treatment methodologies and risk factors. Monotherapy PPB used either I-125 or Pd-103 prescribed to 144 Gy (TG-43) or 140 Gy (NIST-99 Standard), respectively. 12, 13 Combined treatment consisted of XRT to 41.4 or 45 Gy and an I-125 or Pd-103 PPB to 108 Gy or 105 Gy, respectively. External radiotherapy was delivered via four pelvic fields with a mean APPA field size of 11 6 11 cm and lateral field size of 11 6 10 cm. The implant was performed by author L.P. between September 1992 and September 2000. A preimplant ultrasound volume was used to assess the prostate dimensions and the total activity required for either Pd-103 or I-125 was determined by using a nomogram for either isotope, respectively. 3, 14 The implant was performed using the B&K (Marlborough, MA) biplane ultrasound probe with peripheral seed loading used to produce as uniform a dose as possible.
Post-implant analysis consisted of stereo shift X-ray films and two-dimensional reconstruction (n ¼ 524) on the day following the implant. As of 1995, patients underwent CT scan based dosimetry at 2 -3 weeks post implant.
Follow-up visits were conducted at 4-month intervals for 12 months, then every 6 months thereafter. A serum prostate specific antigen (PSA) level was obtained and digital rectal examination was performed at each followup. Patients were entered into a database (ProstaBase). Any patients lacking a scheduled follow-up visit were contacted to have a PSA test. All raw follow-up PSA values were provided to allow for a standardized definition of PSA failure across treatment cohorts. The American Society for Therapeutic Radiology and Oncology (ASTRO) definition of PSA failure following external beam radiotherapy was applied with modification. 15 This definition marks failure at the midpoint in time between the post-treatment nadir and the first of three consecutive PSA rises. However, two important conservative modifications were made. 16 First, the requirement that the three rises have to be consecutive was relaxed. This identification represents an increase in sensitivity over the ASTRO definition that only fails the patient when the rises are consecutive. Second, for patients whose most recent PSA values were rising at the time of their last follow-up, but in whom failure had not occurred, follow-up time was truncated at the PSA immediately prior to the first rise. This technique reduces the 'backdating' problem associated with the ASTRO definition. With this early censoring adjustment, patients with equivocal PSA values are not considered disease-free beyond the time of the nadir PSA value, as they would be with ASTRO. The net effect of these modifications is to increase the number of failures and to reduce the survival time granted to the censored patients, both of which lower the freedom from recurrence curve and artificially shorten the follow-up time. Clinical relapse, death from disease, and secondary treatments were also considered treatment failures if they occurred prior to a PSA failure.
Risk group assignment was based on a pretreatment PSA value 10 ng/ml and Gleason score 2 -6. Those meeting both criteria were considered low risk. Those patients failing one criteria were considered intermediate risk and those failing both criteria were considered high risk.
Wilcoxon testing of risk factors based on treatment modality was undertaken and Cox regression hazards analysis was performed. 17 A computer generated matching process was undertaken from the entire patient cohort to produce two equally weighted pairs of patients divided by treatment methodology; CMT or monotherapy. Additional testing of risk factors between the matched groups were performed. Kaplan-Meier PSA-RFS curves were generated and compared by w 2 testing. 18 
Results
Patient characteristics are presented in Table 1 . The median follow-up from this study cohort is 34.7 months (6 -91 months). The overall and disease specific survival are 97% and 100%, respectively. A total of 87% of patients obtained a PSA value within the last year of follow-up and the characteristics of recurrence are presented in Table 2 . Thirty six patients were lost to follow-up and are censored based on their last PSA value. The PSA-RFS form the entire cohort is 81.9%. Figure 1 demonstrates the PSA-RFS comparing monotherapy versus CMT for all patients (P ¼ 0.542).
The difference in presenting characteristics between those patients treated with CMT or monotherapy and are presented in Table 1 . Patients treated with CMT were found to present with higher Gleason sum scores, pretreatment PSA values, higher stage, were in a higher risk grouping and were more likely to be treated with NAAD. Multivariate analysis identified the pretreatment PSA value and Gleason sum score as significant factors to predict PSA-RFS (Table 3) .
A computer-generated process was able to generate two evenly matched groups of patients based on whether they received monotherapy or CMT. These groups were stratified from the entire cohort according to the use of NAAD, the Gleason sum score and the pretreatment PSA value (Table 4) with an outcome that created two matched patient populations without significant differences between them for the stratification factors. Overall, there was no difference in PSA-RFS for patients treated with CMT versus monotherapy, respectively (81.1% vs 77.0%; P ¼ 0.542, Figure 2) . No difference in PSA-RFS between groups was observed for Gleason sum score ( 6 vs > 6, P ¼ 0.641), pretreatment PSA value ( 10 ng/ml vs > 10 ng/ml, P ¼ 0.275) and assigned risk group (low risk group P ¼ 0.640, intermediate risk group P ¼ 0.491, high risk group P ¼ 0.65, Table 5 , Figures 3, 4 and 5) , although an absolute 8% percent improvement in PSA-RFS was observed for the high risk patients. Risk groups defined by using the pretreatment PSA 10 ng/ml and Gleason sum score 6. Those meeting both criteria are considered low risk, those with one are intermediate, and those failing both are high-risk. Role for combined radiotherapy and brachytherapy in prostate cancer L Potters et al
Discussion
The data presented in this study failed to identify a significant advantage for combining radiation therapy and brachytherapy for all risk patients with localized prostate cancer when using PSA-RFS as an endpoint. Using the entire study cohort, CMT was not a significant factor on Cox regression hazards analysis. To further stratify and better match for known prognostic factors, a computer generated matching created two sets of evenly stratified patients. CMT offered no improvement in PSA-RFS compared with monotherapy. However, a trend toward improved outcome in the high-risk group of patients with an absolute difference of 8% in PSA-FRS was seen. Role for combined radiotherapy and brachytherapy in prostate cancer L Potters et al
The rational for combining external radiation and brachytherapy is based on the need to expand the sphere of radiation dose beyond the prostate capsule when patients exhibit a high risk that may predict for extracapsular disease. Several surgical series have been able to determine the statistical risk that is stratified by the pretreatment PSA value, Gleason sum score and clinical stage. 19 Nonetheless, a recent study from Davis et al, examined prostate specimens from patients with clinical T1c disease undergoing radical prostatectomy and was able to determine that pathologic focal extracapsular disease was within 3.3 mm of the prostate capsule over 90% of the time and that the maximum distance of disease was 1.2 cm. 20 With modern transperineal brachytherapy techniques, the dosimetry will usually encompass an extra prostatic margin that may cover and treat this area of extracapsular risk.
Ragde et al, demonstrated in a study presenting 12-y crude outcome data, that patients treated with CMT had a 79% biochemical control rate as compared to a 66% 12-y biochemical control rate using monotherapy. 21 Unfortunately, these authors did not stratify their patients or perform comparative analysis between these two groups and despite the reported differences in outcome, they concluded that the need for CMT remains questionable. In another study, Blasko et al, have presented their experience of CMT and monotherapy and identified an improvement in PSA-RFS for the monotherapy subset as compared to the CMT subset (88% vs 79% 8-y PSA-RFS, respectively). 22 The authors identified that the CMT patient subset had higher risk factors, and to account for this, they stratified their patients in a like manor as the current study by risk groups. No difference was identified for each risk subset between patients treated with CMT or monotherapy.
In the present study, the matched pair analysis provided two evenly paired groups of patients stratified by the use of NAAD, the pretreatment PSA value and the Gleason sum score. While no statistical difference in PSA-RFS survival was identified regardless of the risk group assignment ( Figures 3, 4 and 5) , a trend toward improved outcome in the high-risk group was seen. Longer followup from this cohort may better identify the role of CMT for this subset of patients.
Another benefit of CMT may be that it accounts for poor quality implants. The analysis of implant quality and the addition of external beam radiation will be the subject of another study. Nonetheless, one consideration for the addition of adding external radiation is to compensate for poor implants. This is different than selecting patients based on prognostic risk and treating a priori with external beam irradiation. Alternatively, the use of intraoperative treatment planning systems may improve our ability to adjust and compensate for irregularities during the procedure that would ensure for consistent and good implant dosimetry. 23 Critz et al, have proposed 'simultaneous irradiation' as another conceptual advantage for the use of brachytherapy with I-125 followed by external radiotherapy. 9 In a recent update of their experience, using a PSA nadir of 0.2 ng/ml as an endpoint, they present an overall 88% 5-y disease-free survival. The use of a nadir definition does not otherwise allow for comparison to other radiation series. Further, the use of a nadir PSA value as evidence of failure is problematic and does not work well for patients treated with radiation when a PSA nadir is not instantaneous. The problem is that one never really knows when the patient has reached a nadir unless his PSA actually drops below the defined nadir value or the patient is declared a failure clinically. Use of Kaplan-Meier to estimate the time-to-event is based specifically on how one defines the censored event. 18 As such, use of the ASTRO definition with either the Vicini or Kattan modification is encouraged and accounts better for the protracted fall in PSA that occurs following radiation. 16, 24 In addition, it allows for comparison of data between series.
Combining therapies may increase treatment toxicities. In two retrospective series examining urinary and rectal complications, Gelblum et al was unable to show that combined therapies are associated with higher treatment related toxicity. 25, 26 Nonetheless, another retrospective series from Zeitlin et al reported a rectoprostatic fistula rate of 2.3% when external radiation follows PPB. 27 Brandeis et al, reported prospective data using quality of life tools that examined either monotherapy or CMT. 28 They found that urinary function and bother, bowel bother, sexual function and bother, AUA symptom score and cancer interference with life were all statistically worse in the CMT group as compared to patients treated with monotherapy. These data seem to indicate that if there is no discernable improvement in outcome, the risk from combined therapy may be unacceptable.
Treatment related cost rises significantly for patients treated with CMT as compared to monotherapy. The delivery of conventional radiation therapy for 25 fractions will almost double the cost of therapy based on the Medicare relative values for utilized CPT codes, even with the cost of the isotope included. 29 Based on the availability of 3-dimensional treatment planning and delivery techniques, coupled with patient sophistication requesting such therapy, the cost of CMT with 3-dimensional radiation and brachytherapy is 2.8 times monotherapy using the relative values of allowable CPT codes. 29 Clearly, as pointed out by Critz et al, the cost of salvage therapy for failure, if the rate of failure is different for each treatment approach, is not being factored into this equation. However, without any data indicating a superior outcome with CMT, its cost clearly is a factor in the current managed care environment.
A review of the literature trying to examine the role of CMT in early stage prostate cancer treated with brachytherapy was undertaken and is presented in Table 6 . However, due to such a wide disparity of reported outcomes and patient stratifications, it is difficult to ascertain any trends between those patients treated with monotherapy or in combination with external radiotherapy. Nonetheless, this review emphasizes that conclusions for either approach cannot easily be defended.
In conclusion, this retrospective matched pair analysis was unable to demonstrate a significant advantage for the addition of external beam irradiation to PPB. This study nonetheless is retrospective and potentially lacks the power to fully delineate the role for combined therapies in clinically localized prostate cancer. The use of a matched pair analysis contributes to the validity of our reported data but prospective data will ultimately be required to fully address the need for combined therapies in patients with prostate cancer. Risk groups defined by using the pretreatment PSA < 10 and Gleason sun score < 6. Those with both are considered low risk, those with one are intermediate, and those failing both are high-risk.
